Matriks metalloproteinazlar ve akciğer kanseri

Hilal Oğuz SOYDİNÇ, Hakan ÇAMLICA, Derya DURANYILDIZ, Esra Kaytan SAĞLAM, Faruk TAŞ, Vildan YASASEVER, Nejat DALAY
446 121

Öz


AMAÇ Bu çalışmada akciğer kanserli hastalarda matriks metalloproteinaz- 9 (MMP-9) ve doku matriks metalloproteinaz inhibitörü- 1'in (TIMP-1) tedavi öncesi düzeylerinin belirlenmesi amaçlandı. GEREÇ VE YÖNTEM Çalışmamızda cerrahi ve radyoterapi uygulanmamış 20 akciğer kanserli hastada MMP-9 ve TIMP-1 değerleri ELISA yöntemi ile belirlendi ve sağlıklı kontrol grubu ile karşılaştırıldı (n=20). BULGULAR Hastaların MMP-9 (p

Anahtar kelimeler


Akciğer neoplazmları,Matriks metalloproteinaz 9,Metalloproteinaz-1 doku inhibitörü,Enzim bağlı immünosorbent tayini

Tam metin:

PDF

Referanslar


1) Topuz E, Aydıner A. Akciğer kanseri. In: Topuz E, Aydıner A, Karadeniz AN, editors. Klinik onkoloji. İstanbul: İ.Ü. Onkoloji Enstitüsü Yayınları; 2000. p. 82-9

2) American Joint Commitee on Cancer (AJCC) Cancer staging manual. 5th ed. Philadelphia: Lippincort- Raven; 1997. p. 127-37

3) Darendeliler E. Akciğer kanserinde radyoterapi. In: Topuz E, editör. Akciğer kanseri. İstanbul: İ.Ü. Onkoloji Enstitüsü Yayınları; 1995. p. 91-102

4) Ohbayashi H. Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 2002;3(4):409-21

5) Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. Proc Natl Acad Sci U S A 1990;87(1):364-8

6) Laack E, Kohler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G, et al. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002;13(10):1550-7

7) Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP, et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase 9 in nonsmall cell lung cancer patients. Clin Chim Acta 2005;354(1-2):91-9

8) Garbisa S, Scagliotti G, Masiero L, Di Francesco C, Caenazzo C, Onisto M, et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 1992;52(16):4548-9

9) Iizasa T, Fujisawa T, Suzuki M, Motohashi S, Yasufuku K, Yasukawa T, et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in nonsmall cell lung cancer patients. Clin Cancer Res 1999;5(1):149-53

10) Susskind H, Hymowitz MH, Lau YH, Atkins HL, Hurewitz AN, Valentine ES, et al. Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy. Int J Radiat Oncol Biol Phys 2003;56(4):1161-9

11) Pinto CA, Carvalho PE, Antonangelo L, Garippo A, Da Silva AG, Soares F, et al. Morphometric evaluation of tumor matrix metalloproteinase 9 predicts survival after surgical resection of adenocarcinoma of the lung. Clin Cancer Res 2003;9(8):3098-104

12) Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer- -TIMP-1 as a prognostic marker. Anticancer Res 2000;20(2B):1311-6

13) Jumper C, Cobos E, Lox C. Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small cell lung cancer prior to treatment. Respir Med 2004;98(2):173-7

14) Leinonen T, Pirinen R, Bohm J, Johansson R, Ropponen K, Kosma VM. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer Relation to clinicopathological factors, beta-catenin and prognosis. Lung Cancer 2006;51(3):313-21

15) Wang J, Miao LJ, Wu YM, Wu YJ, Wang XC. Expression of AKT2, Cyclin D1, and MMP-9 and Their Correlations to Clinicopathologic Features of Non-small Cell Lung Cancer. [Article in Chinese] Ai Zheng 2006;25(1):69-72.